Anti-cancer Metabolism Compound Library: Selection & Usage Guide
Anti-cancer Metabolism Compound Library: Selection & Usage Guide
Anti-cancer Metabolism Compound Library is a curated collection of bioactive small molecules targeting key metabolic pathways implicated in tumor survival and proliferation, providing researchers with a powerful tool for identifying novel cancer metabolism therapeutics.
- Product Name
- Anti-cancer Metabolism Compound Library
- SKU
- Lib412061
- Selleck Reference Number
- L5700
- Application
- Anti-tumor metabolic pathway screening and drug discovery
- Recommended Use
- In vitro high-throughput and medium-throughput screening assays
- Storage Recommendation
- Store as supplied; avoid repeated freeze-thaw cycles (see SDS for exact conditions)
Scientific Rationale: Why Target Cancer Metabolism?
Reprogrammed cellular metabolism is a hallmark of cancer. Tumor cells preferentially utilize aerobic glycolysis (the Warburg effect), glutamine catabolism, lipid biosynthesis, and one-carbon metabolism to meet the biosynthetic and energetic demands of rapid proliferation. These metabolic dependencies create selective vulnerabilities that can be exploited pharmacologically without equivalent toxicity to normal, quiescent tissues.
Key pathways of therapeutic interest include glycolysis (HK2, LDHA, PKM2), the pentose phosphate pathway, the TCA cycle, oxidative phosphorylation, fatty acid oxidation and synthesis (FASN, ACC), glutaminolysis (GLS), and mTOR/AMPK energy-sensing nodes. Compounds that modulate these nodes can suppress tumor growth, overcome drug resistance, and sensitize cells to standard-of-care therapies.
The Anti-cancer Metabolism Compound Library (Lib412061) aggregates pharmacological tools targeting these pathways into a single, ready-to-screen collection, accelerating the identification of lead compounds and mechanistic probes.
Library Composition and Coverage
The Anti-cancer Metabolism Compound Library (Selleck Number L5700) is a structurally diverse collection of small molecules with demonstrated or reported activity against targets involved in tumor metabolic reprogramming. The library spans multiple mechanistic classes, including:
- Glycolysis inhibitors — targeting hexokinase, phosphofructokinase, pyruvate kinase isoforms, and lactate dehydrogenase.
- Mitochondrial function modulators — compounds affecting the electron transport chain, ATP synthase, and mitochondrial membrane potential.
- Glutamine metabolism inhibitors — targeting glutaminase (GLS/GLS2) and downstream amination reactions.
- Lipid metabolism modulators — fatty acid synthase (FASN) inhibitors, ACC inhibitors, and CPT1 modulators.
- mTOR/PI3K/AMPK pathway compounds — linking nutrient sensing to anabolic metabolism.
- One-carbon and folate metabolism inhibitors — affecting serine, glycine, and methionine utilization.
Each compound is supplied as a pre-dissolved DMSO stock solution at defined concentration to facilitate direct plate-based screening. Purity and identity are confirmed by HPLC and mass spectrometry prior to dispatch.
Recommended Screening Workflow
The following stepwise workflow is recommended to maximize data quality when using the Anti-cancer Metabolism Compound Library:
- Assay development and validation — Select a cell-based or biochemical assay appropriate for your metabolic endpoint of interest (e.g., Seahorse XF assay for oxygen consumption rate, fluorometric lactate or glucose uptake assays, or cell-viability readouts). Validate assay window (Z-factor ≥ 0.5) before library screening.
- Compound preparation — Thaw library plates at room temperature, centrifuge briefly (1 000 × g, 1 min) to collect contents, then dilute into assay medium. Recommended primary screening concentration: 1–10 µM. Maintain DMSO ≤ 0.1 % (v/v) in final assay volume.
- Primary screening — Run compounds in single duplicate against positive and negative controls on each plate. Flag hits exhibiting ≥ 50 % inhibition (or activation) relative to controls.
- Dose-response confirmation — Retest primary hits in 8- to 10-point concentration-response curves (CRC) to determine IC₅₀ or EC₅₀ values and confirm reproducibility.
- Counter-screening and selectivity profiling — Assess cytotoxicity in non-cancerous cell lines to establish therapeutic index. Orthogonal biochemical assays confirm on-target activity.
- Mechanistic follow-up — Validated hits proceed to metabolomics (LC-MS/MS), Western blot, or CRISPR-based target validation studies.
Maintain a detailed screening log including lot numbers, thaw dates, and DMSO exposure times to ensure reproducibility across runs.
Handling, Storage, and Quality Considerations
Proper handling of the Anti-cancer Metabolism Compound Library is critical for maintaining compound integrity and assay reproducibility:
- Storage: Store sealed library plates according to the conditions specified in the accompanying Certificate of Analysis (CoA) and Safety Data Sheet (SDS). Many metabolic inhibitors are sensitive to moisture and light; store desiccated and protected from direct illumination.
- Freeze-thaw cycles: Minimize the number of freeze-thaw cycles. Aliquot master stock plates into working plates upon first use to preserve remaining compound for confirmatory studies.
- DMSO quality: Use anhydrous, molecular-biology-grade DMSO for any dilution steps. Water-contaminated DMSO can precipitate compounds and reduce effective concentration.
- Solubility verification: Visually inspect diluted solutions for particulates before addition to assay plates. If precipitation is observed, brief sonication (30 s) in a water bath followed by vortexing may restore solubility; note this in the screening log.
- Documentation: Record lot number (Lib412061), Selleck reference (L5700), date of receipt, storage conditions, and all handling events for GLP-aligned traceability.
Consult the product-specific CoA for purity specifications (typically ≥ 95 % by HPLC) and mass confirmation data. For regulatory or publication purposes, request a full analytical data package from Aladdin Scientific at the time of order.
Applications and Research Utility
The Anti-cancer Metabolism Compound Library is suited to a broad range of research and drug-discovery applications:
- Phenotypic screening: Identify compounds that selectively impair cancer cell proliferation or viability through metabolic mechanisms in 2D monolayer, 3D spheroid, or organoid models.
- Target identification and validation: Use library members as pharmacological probes to link specific metabolic enzymes to oncogenic phenotypes.
- Combination therapy discovery: Pair library compounds with standard chemotherapeutics, targeted agents, or immunotherapy modulators to identify synergistic combinations that overcome resistance.
- Biomarker studies: Correlate compound sensitivity profiles with metabolomics, genomic, or proteomic datasets to identify predictive biomarkers for patient stratification.
- Academic and translational research: Suitable for university laboratories, cancer research institutes, and biotech drug-discovery teams exploring the intersection of metabolism and oncology.
Results obtained with this library can directly inform lead optimization programs and support grant applications or proof-of-concept publications in cancer metabolism.
Frequently asked questions
What is the Anti-cancer Metabolism Compound Library and what does it target?
The Anti-cancer Metabolism Compound Library (Lib412061, Selleck L5700) is a curated set of bioactive small molecules designed to inhibit or modulate metabolic pathways preferentially active in tumor cells. Targets span glycolysis, glutaminolysis, lipid metabolism, mitochondrial respiration, and nutrient-sensing kinase pathways such as mTOR and AMPK.
What DMSO concentration is safe to use during screening with this library?
For most cell-based assays, the final DMSO concentration in the assay volume should be kept at or below 0.1 % (v/v) to avoid solvent-induced cytotoxicity or metabolic interference. Always include a DMSO vehicle control at the same concentration as the highest compound-treated wells to allow accurate normalization of results.
How should I store the library to maintain compound integrity?
Store the Anti-cancer Metabolism Compound Library plates sealed, desiccated, and protected from light under conditions specified in the CoA and SDS. Minimize freeze-thaw cycles by aliquoting master plates into working copies upon first use. Use only anhydrous, high-purity DMSO for dilutions, as moisture contamination can cause compound precipitation and loss of potency.
Can this library be used for combination therapy studies?
Yes. The library is well-suited for combination screening experiments where individual metabolic inhibitors are paired with chemotherapeutics, targeted kinase inhibitors, or immunomodulatory agents. Matrix-format combination assays can be used to calculate synergy scores (e.g., Bliss independence, Loewe additivity) and prioritize combinations for further in vivo validation.
What quality controls are applied to the Anti-cancer Metabolism Compound Library?
Each compound in the Anti-cancer Metabolism Compound Library undergoes purity verification by HPLC and identity confirmation by mass spectrometry before dispatch. A Certificate of Analysis (CoA) is provided with every shipment. Researchers requiring additional analytical documentation should contact Aladdin Scientific at the time of ordering.
References
- Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674. doi:10.1016/j.cell.2011.02.013
- Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029-1033. doi:10.1126/science.1160809
- DeBerardinis RJ, Chandel NS. Fundamentals of cancer metabolism. Science Advances. 2016;2(5):e1600200. doi:10.1126/sciadv.1600200
- Luengo A, Gui DY, Vander Heiden MG. Targeting metabolism for cancer therapy. Cell Chemical Biology. 2017;24(9):1161-1180. doi:10.1016/j.chembiol.2017.08.028
Products are supplied for research and development use only. Not for use in humans, animals, diagnosis, or therapy.
